Short answer
ALUMIS INC. (ALMS) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Alumis fiscal quarter ended September 30, 2026.
ALUMIS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Alumis fiscal quarter ended September 30, 2026
- Exhibit 99.1 contains the company’s financial results and accompanying management disclosures
- Investor focus: quarterly performance details, cash position, and forward outlook in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $1.9M versus $2.1M, while net loss improved to $94.9M from $110.8M
- Cash, equivalents and marketable securities $431.3M, supporting operations and capital needs into Q4 2027
- Envudeucitinib psoriasis data showed 54% PASI 100 response at Week 48, with NDA submission still targeted for Q4 2026
- LUMUS missed primary and secondary endpoints overall in SLE, though IFNGS-high subgroup responses support regulatory discussions
- R&D spending fell to $80.8M from $97.8M as pivotal psoriasis trials progressed, partially offset by ONWARD3 costs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ALUMIS INC. 8-K filings
Get the next ALMS 8-K as it lands
Follow ALMS for push alerts, or ask the research agent what this filing means.